MX2018013983A - Inhibidores g12c de kras. - Google Patents

Inhibidores g12c de kras.

Info

Publication number
MX2018013983A
MX2018013983A MX2018013983A MX2018013983A MX2018013983A MX 2018013983 A MX2018013983 A MX 2018013983A MX 2018013983 A MX2018013983 A MX 2018013983A MX 2018013983 A MX2018013983 A MX 2018013983A MX 2018013983 A MX2018013983 A MX 2018013983A
Authority
MX
Mexico
Prior art keywords
kras
inhibitors
compounds
relates
present
Prior art date
Application number
MX2018013983A
Other languages
English (en)
Inventor
F Blake James
Joseph Chicarelli Mark
E Burgess Laurence
p tang Tony
James Hicken Erik
P Fischer John
Jay Hinklin Ronald
Arnold Marx Matthew
Gail Christensen James
Bradford Fell Jay
J Mejia Macedonio
J Gaudino John
P A Vigers Guy
Randolf Lee Matthew
SAVECHENKOV Pavel
J Zecca Henry
Original Assignee
Mirati Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mirati Therapeutics Inc filed Critical Mirati Therapeutics Inc
Publication of MX2018013983A publication Critical patent/MX2018013983A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • H—ELECTRICITY
    • H05—ELECTRIC TECHNIQUES NOT OTHERWISE PROVIDED FOR
    • H05K—PRINTED CIRCUITS; CASINGS OR CONSTRUCTIONAL DETAILS OF ELECTRIC APPARATUS; MANUFACTURE OF ASSEMBLAGES OF ELECTRICAL COMPONENTS
    • H05K999/00—PRINTED CIRCUITS; CASINGS OR CONSTRUCTIONAL DETAILS OF ELECTRIC APPARATUS; MANUFACTURE OF ASSEMBLAGES OF ELECTRICAL COMPONENTS dummy group
    • H05K999/99—PRINTED CIRCUITS; CASINGS OR CONSTRUCTIONAL DETAILS OF ELECTRIC APPARATUS; MANUFACTURE OF ASSEMBLAGES OF ELECTRICAL COMPONENTS dummy group dummy group

Abstract

La presente invencion se refiere a compuestos que inhiben a G12C KRas; en particular, la presente invencion se refiere a compuestos que inhiben irreversiblemente la actividad de G12C KRas, composiciones farmaceuticas que comprenden los compuestos y metodos de uso para estos.
MX2018013983A 2016-05-18 2017-05-17 Inhibidores g12c de kras. MX2018013983A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662338116P 2016-05-18 2016-05-18
US201762444614P 2017-01-10 2017-01-10
PCT/US2017/033099 WO2017201161A1 (en) 2016-05-18 2017-05-17 Kras g12c inhibitors

Publications (1)

Publication Number Publication Date
MX2018013983A true MX2018013983A (es) 2019-08-16

Family

ID=60326411

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018013983A MX2018013983A (es) 2016-05-18 2017-05-17 Inhibidores g12c de kras.

Country Status (12)

Country Link
US (3) US11267812B2 (es)
EP (1) EP3458445B1 (es)
JP (1) JP7039489B2 (es)
KR (1) KR102444509B1 (es)
CN (1) CN109843856B (es)
AU (1) AU2017266911B2 (es)
CA (1) CA3024523A1 (es)
ES (1) ES2863873T3 (es)
IL (1) IL262867B (es)
MX (1) MX2018013983A (es)
SG (1) SG11201810171SA (es)
WO (1) WO2017201161A1 (es)

Families Citing this family (145)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017266911B2 (en) 2016-05-18 2021-09-02 Array Biopharma, Inc. KRas G12C inhibitors
BR112019012976A2 (pt) 2016-12-22 2019-12-31 Amgen Inc inibidores de kras g12c e métodos de uso dos mesmos
JOP20190272A1 (ar) 2017-05-22 2019-11-21 Amgen Inc مثبطات kras g12c وطرق لاستخدامها
IL293443A (en) 2017-09-08 2022-07-01 Amgen Inc kras g12c inhibitors and methods of using them
HUE061599T2 (hu) * 2017-11-15 2023-07-28 Mirati Therapeutics Inc KRas G12C inhibotorok
US10647715B2 (en) 2017-11-15 2020-05-12 Mirati Therapeutics, Inc. KRas G12C inhibitors
US10597405B2 (en) 2017-12-08 2020-03-24 Astrazeneca Ab Chemical compounds
CN112442030B (zh) * 2018-01-19 2022-09-27 南京明德新药研发有限公司 作为krasg12c突变蛋白抑制剂的吡啶酮并嘧啶类衍生物
TW201942115A (zh) * 2018-02-01 2019-11-01 美商輝瑞股份有限公司 作為抗癌藥之經取代的喹唑啉和吡啶並嘧啶衍生物
TW201942116A (zh) 2018-02-09 2019-11-01 美商輝瑞股份有限公司 作為抗癌劑之四氫喹唑啉衍生物
WO2019195609A2 (en) * 2018-04-04 2019-10-10 Arvinas Operations, Inc. Modulators of proteolysis and associated methods of use
CA3099118A1 (en) 2018-05-04 2019-11-07 Amgen Inc. Kras g12c inhibitors and methods of using the same
WO2019213516A1 (en) * 2018-05-04 2019-11-07 Amgen Inc. Kras g12c inhibitors and methods of using the same
WO2019217307A1 (en) 2018-05-07 2019-11-14 Mirati Therapeutics, Inc. Kras g12c inhibitors
TW202012415A (zh) 2018-05-08 2020-04-01 瑞典商阿斯特捷利康公司 化學化合物
CA3099045A1 (en) 2018-05-10 2019-11-14 Amgen Inc. Kras g12c inhibitors for the treatment of cancer
US11096939B2 (en) 2018-06-01 2021-08-24 Amgen Inc. KRAS G12C inhibitors and methods of using the same
WO2020050890A2 (en) * 2018-06-12 2020-03-12 Amgen Inc. Kras g12c inhibitors and methods of using the same
CN112119075B (zh) 2018-08-16 2024-03-12 豪夫迈·罗氏有限公司 稠环化合物
ES2961253T3 (es) 2018-08-31 2024-03-11 Mirati Therapeutics Inc Inhibidores de KRas G12C
WO2020055755A1 (en) * 2018-09-10 2020-03-19 Mirati Therapeutics, Inc. Combination therapies
EP3849536A4 (en) * 2018-09-10 2022-06-29 Mirati Therapeutics, Inc. Combination therapies
AU2019338207A1 (en) * 2018-09-10 2021-04-29 Mirati Therapeutics, Inc. Combination therapies
JP2022500379A (ja) * 2018-09-10 2022-01-04 ミラティ セラピューティクス， インコーポレイテッド 組み合わせ療法
JP2022500388A (ja) * 2018-09-10 2022-01-04 ミラティ セラピューティクス， インコーポレイテッド 組み合わせ療法
EP3853233A1 (en) 2018-09-18 2021-07-28 Nikang Therapeutics, Inc. Tri-substituted heteroaryl derivatives as src homology-2 phosphatase inhibitors
EP3856719B1 (en) 2018-09-30 2023-06-07 XWPharma Ltd. Compounds as neuronal histamine receptor-3 antagonists and uses thereof
MA51530A (fr) * 2018-11-09 2021-04-21 Hoffmann La Roche Composés cycliques fondus
JP2020090482A (ja) 2018-11-16 2020-06-11 アムジエン・インコーポレーテツド Ｋｒａｓ ｇ１２ｃ阻害剤化合物の重要な中間体の改良合成法
WO2020106640A1 (en) 2018-11-19 2020-05-28 Amgen Inc. Kras g12c inhibitors and methods of using the same
JP7377679B2 (ja) 2018-11-19 2023-11-10 アムジエン・インコーポレーテツド がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法
US20220079947A1 (en) * 2018-12-05 2022-03-17 Mirati Therapeutics, Inc. Combination therapies
WO2020146613A1 (en) 2019-01-10 2020-07-16 Mirati Therapeutics, Inc. Kras g12c inhibitors
EP4249000A3 (en) 2019-02-12 2023-12-27 Novartis AG Pharmaceutical combination comprising tno155 and a krasg12c inhibitor
EP3738593A1 (en) 2019-05-14 2020-11-18 Amgen, Inc Dosing of kras inhibitor for treatment of cancers
MX2021014177A (es) * 2019-05-20 2022-04-25 California Inst Of Techn Inhibidores de kras con la mutacion de glicina a cisteina en el codon 12 (g12c) y usos de los mismos.
EP3972963A1 (en) 2019-05-21 2022-03-30 Bayer Aktiengesellschaft Identification and use of kras inhibitors
JOP20210310A1 (ar) 2019-05-21 2023-01-30 Amgen Inc أشكال الحالة الصلبة
TW202110837A (zh) * 2019-05-24 2021-03-16 大陸商江蘇恆瑞醫藥股份有限公司 氫化吡啶并嘧啶類衍生物、其製備方法及其在醫藥上的應用
CA3139769A1 (en) * 2019-05-29 2020-12-03 Shiqiang Liu Nitrogen-containing heterocyclic derivative regulator, preparation method therefor and application thereof
CN112047939B (zh) * 2019-06-06 2023-05-02 江苏先声药业有限公司 一种具有抗肿瘤活性的四氢吡啶并嘧啶类化合物
TW202115089A (zh) * 2019-07-01 2021-04-16 大陸商江蘇恆瑞醫藥股份有限公司 喹唑啉酮類衍生物、其製備方法及其在醫藥上的應用
CN112300153B (zh) * 2019-07-26 2023-06-13 博瑞生物医药（苏州）股份有限公司 一种杂环化合物、药物组合物和用途
CN112390788A (zh) * 2019-08-13 2021-02-23 苏州闻天医药科技有限公司 一种用于抑制krasg12c突变蛋白的化合物及其制备方法和用途
CN112390797A (zh) * 2019-08-15 2021-02-23 微境生物医药科技(上海)有限公司 新型螺环类K-Ras G12C抑制剂
CN112390796B (zh) * 2019-08-19 2023-06-27 贝达药业股份有限公司 Kras g12c抑制剂及其在医药上的应用
CN112430234B (zh) * 2019-08-26 2023-04-28 信达生物制药(苏州)有限公司 一种新型kras g12c蛋白抑制剂及其制备方法和用途
AU2020337938A1 (en) 2019-08-29 2022-03-17 Array Biopharma Inc. KRas G12D inhibitors
WO2021043322A1 (zh) * 2019-09-06 2021-03-11 正大天晴药业集团南京顺欣制药有限公司 氮杂环庚烷并嘧啶类衍生物及其医药用途
WO2021055728A1 (en) * 2019-09-18 2021-03-25 Merck Sharp & Dohme Corp. Small molecule inhibitors of kras g12c mutant
CN112538084B (zh) * 2019-09-23 2023-06-20 信达生物制药(苏州)有限公司 新颖的kras g12c蛋白抑制剂及其制备方法和用途
EP4034123A4 (en) 2019-09-24 2023-11-01 Mirati Therapeutics, Inc. COMBINATION THERAPIES
CN114555586B (zh) * 2019-10-10 2023-06-23 信达生物制药(苏州)有限公司 Krasg12c蛋白抑制剂及其制备方法和用途
CN112694475A (zh) * 2019-10-23 2021-04-23 苏州泽璟生物制药股份有限公司 环烷基类和杂环烷基类抑制剂及其制备方法和应用
JP7340100B2 (ja) 2019-10-28 2023-09-06 メルク・シャープ・アンド・ドーム・エルエルシー Ｋｒａｓ ｇ１２ｃ変異型の小分子阻害薬
US11739074B2 (en) 2019-11-04 2023-08-29 Revolution Medicines, Inc. Ras inhibitors
AU2020379734A1 (en) 2019-11-04 2022-05-05 Revolution Medicines, Inc. Ras inhibitors
CA3160142A1 (en) 2019-11-04 2021-05-14 Revolution Medicines, Inc. Ras inhibitors
CN112778301A (zh) * 2019-11-07 2021-05-11 苏州泽璟生物制药股份有限公司 四氢吡啶并嘧啶类抑制剂及其制备方法和应用
TWI760919B (zh) * 2019-11-15 2022-04-11 大陸商四川海思科製藥有限公司 一種嘧啶並環衍生物及其在醫藥上的應用
CN112824410A (zh) * 2019-11-21 2021-05-21 苏州泽璟生物制药股份有限公司 氮杂七元环类抑制剂及其制备方法和应用
CN114980976A (zh) 2019-11-27 2022-08-30 锐新医药公司 共价ras抑制剂及其用途
WO2021106231A1 (en) * 2019-11-29 2021-06-03 Taiho Pharmaceutical Co., Ltd. A compound having inhibitory activity against kras g12d mutation
CN112979664B (zh) * 2019-12-02 2024-03-01 上海璎黎药业有限公司 一种含氧杂环化合物、其制备方法及应用
WO2021109737A1 (zh) * 2019-12-02 2021-06-10 上海璎黎药业有限公司 一种含氧杂环化合物、其制备方法及应用
WO2021120890A1 (en) 2019-12-20 2021-06-24 Novartis Ag Pyrazolyl derivatives useful as anti-cancer agents
CN115135315A (zh) 2019-12-20 2022-09-30 米拉蒂治疗股份有限公司 Sos1抑制剂
CN113045565A (zh) * 2019-12-27 2021-06-29 微境生物医药科技(上海)有限公司 新型K-Ras G12C抑制剂
CN112094269B (zh) * 2020-01-01 2021-12-07 上海凌达生物医药有限公司 一类饱和六元环并杂环类化合物、制备方法和用途
GB202001344D0 (en) 2020-01-31 2020-03-18 Redx Pharma Plc Ras Inhibitors
WO2021168193A1 (en) * 2020-02-20 2021-08-26 Beta Pharma, Inc. Pyridopyrimidine derivatives as kras inhibitors
CN115298174B (zh) * 2020-03-12 2023-11-03 德昇济医药(无锡)有限公司 嘧啶并杂环类化合物及其应用
TWI811656B (zh) * 2020-04-22 2023-08-11 大陸商德昇濟醫藥（無錫）有限公司 嘧啶并雜環類化合物及其應用
TW202144349A (zh) * 2020-04-30 2021-12-01 大陸商上海科州藥物研發有限公司 作為ｋｒａｓ抑制劑的雜環化合物的製備及其應用方法
US11739102B2 (en) 2020-05-13 2023-08-29 Incyte Corporation Fused pyrimidine compounds as KRAS inhibitors
CN113666923A (zh) * 2020-05-15 2021-11-19 苏州泽璟生物制药股份有限公司 烷氧基烷基取代杂环基类抑制剂及其制备方法和应用
KR20230019462A (ko) 2020-06-02 2023-02-08 베링거 인겔하임 인터내셔날 게엠베하 암 치료용 고리형 2-아미노-3-시아노 티오펜 및 유도체
CN111646910A (zh) * 2020-06-15 2020-09-11 中国药科大学 一种盐酸达泊西汀消旋体的制备方法
WO2021257736A1 (en) 2020-06-18 2021-12-23 Revolution Medicines, Inc. Methods for delaying, preventing, and treating acquired resistance to ras inhibitors
US20230233568A1 (en) 2020-06-24 2023-07-27 Boehringer Ingelheim International Gmbh Anticancer combination therapy
CN113912608B (zh) * 2020-07-10 2023-07-14 江苏恒瑞医药股份有限公司 嘧啶并嘧啶酮类衍生物、其制备方法及其在医药上的应用
CN113980014B (zh) * 2020-07-27 2023-05-12 江苏恒瑞医药股份有限公司 氢化吡啶并嘧啶类衍生物、其制备方法及其在医药上的应用
CN116209438A (zh) 2020-09-03 2023-06-02 锐新医药公司 使用sos1抑制剂治疗具有shp2突变的恶性疾病
WO2022052895A1 (zh) 2020-09-11 2022-03-17 南京明德新药研发有限公司 氮杂环丁烷取代化合物的晶型
CN116457358A (zh) 2020-09-15 2023-07-18 锐新医药公司 作为ras抑制剂以治疗癌症的吲哚衍生物
WO2022066646A1 (en) * 2020-09-22 2022-03-31 Mirati Therapeutics, Inc. Kras g12d inhibitors
US20230365563A1 (en) * 2020-09-30 2023-11-16 Shanghai Pharmaceuticals Holding Co., Ltd. Quinazoline compound and application thereof
WO2022087375A1 (en) * 2020-10-22 2022-04-28 Spectrum Pharmaceuticals, Inc. Novel heterocyclic compounds
WO2022087371A1 (en) * 2020-10-22 2022-04-28 Spectrum Pharmaceuticals, Inc. Novel bicyclic compounds
WO2022105855A1 (en) * 2020-11-20 2022-05-27 Jacobio Pharmaceuticals Co., Ltd. Kras g12d inhibitors
KR102503336B1 (ko) 2020-11-23 2023-02-23 동의대학교 산학협력단 음성지원이 가능한 반려동물의 배변 처리 패드
EP4262803A1 (en) * 2020-12-16 2023-10-25 Mirati Therapeutics, Inc. Tetrahydropyridopyrimidine pan-kras inhibitors
US20230107642A1 (en) 2020-12-18 2023-04-06 Erasca, Inc. Tricyclic pyridones and pyrimidones
WO2022140246A1 (en) 2020-12-21 2022-06-30 Hangzhou Jijing Pharmaceutical Technology Limited Methods and compounds for targeted autophagy
CA3202355A1 (en) 2020-12-22 2022-06-30 Jiping Fu Compounds for degrading cyclin-dependent kinase 2 via ubiquitin proteosome pathway
US20240092803A1 (en) * 2021-01-08 2024-03-21 Beigene Switzerland Gmbh Bridged compounds as kras g12d inhibitor and degrader and the use thereof
AU2022212151A1 (en) * 2021-02-01 2023-08-17 Medshine Discovery Inc. Pyrimidopyran compound
WO2022170947A1 (zh) * 2021-02-09 2022-08-18 苏州阿尔脉生物科技有限公司 一类作为kras突变体g12c抑制剂的四氢萘啶类衍生物、其制备方法及其应用
WO2022171143A1 (zh) * 2021-02-09 2022-08-18 南京明德新药研发有限公司 5,6,7,8-四氢吡啶[3,4-d]嘧啶化合物
EP4281457A1 (en) * 2021-03-10 2023-11-29 Beta Pharma, Inc. Pyridopyrimidine derivatives as kras inhibitors
WO2022194192A1 (zh) * 2021-03-18 2022-09-22 四川科伦博泰生物医药股份有限公司 一类杂芳环化合物、其制备方法及用途
CN115124524A (zh) * 2021-03-26 2022-09-30 浙江海正药业股份有限公司 三环类衍生物及其制备方法和用途
JP2024513492A (ja) 2021-04-08 2024-03-25 ミラティ セラピューティクス、インコーポレイテッド がんの治療のためのｐｒｍｔ５阻害剤を使用する併用療法
EP4319757A1 (en) 2021-04-09 2024-02-14 Boehringer Ingelheim International GmbH Anticancer therapy
WO2022217042A1 (en) * 2021-04-09 2022-10-13 Ikena Oncology, Inc. Naphthyl-substituted quinoline-4(1h)-ones and related compounds and their use in treating medical conditions
EP4322954A1 (en) * 2021-04-16 2024-02-21 Merck Sharp & Dohme LLC Small molecule inhibitors of kras g12d mutant
CN117203208A (zh) * 2021-04-23 2023-12-08 清华大学 靶向活化与失活态kras g12d的抑制剂
EP4334321A1 (en) 2021-05-05 2024-03-13 Revolution Medicines, Inc. Ras inhibitors
WO2022235870A1 (en) 2021-05-05 2022-11-10 Revolution Medicines, Inc. Ras inhibitors for the treatment of cancer
EP4347041A1 (en) * 2021-05-28 2024-04-10 Taiho Pharmaceutical Co., Ltd. Small molecule inhibitors of kras mutated proteins
WO2022261210A1 (en) * 2021-06-08 2022-12-15 Quanta Therapeutics, Inc. Kras modulators and uses thereof
WO2022266206A1 (en) 2021-06-16 2022-12-22 Erasca, Inc. Kras inhibitor conjugates
WO2022269508A1 (en) 2021-06-23 2022-12-29 Novartis Ag Pyrazolyl derivatives as inhibitors of the kras mutant protein
TW202317100A (zh) 2021-06-23 2023-05-01 瑞士商諾華公司 包含ｋｒａｓ ｇ１２ｃ抑制劑的藥物組合及其用於治療癌症之用途
WO2022271823A1 (en) * 2021-06-23 2022-12-29 Newave Pharmaceutical Inc. Mutant kras modulators and uses thereof
CN117460737A (zh) * 2021-07-05 2024-01-26 四川科伦博泰生物医药股份有限公司 杂芳环化合物、其制备方法及用途
TW202317589A (zh) 2021-07-14 2023-05-01 美商尼坎醫療公司 作為ｋｒａｓ抑制劑的伸烷基衍生物
WO2023283933A1 (en) * 2021-07-16 2023-01-19 Silexon Biotech Co., Ltd. Compounds useful as kras g12d inhibitors
CN117157292A (zh) * 2021-07-16 2023-12-01 苏州赞荣医药科技有限公司 Kras g12d抑制剂和其用途
CA3227706A1 (en) 2021-07-27 2023-02-02 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
AU2022336415A1 (en) 2021-09-01 2024-01-04 Novartis Ag Pharmaceutical combinations comprising a tead inhibitor and uses thereof for the treatment of cancers
WO2023040989A1 (en) * 2021-09-16 2023-03-23 Suzhou Zanrong Pharma Limited Kras g12c inhibitors and uses thereof
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras
TW202334138A (zh) * 2021-11-05 2023-09-01 美商新領域醫藥公司 癌症治療方法
WO2023098425A1 (zh) * 2021-12-02 2023-06-08 上海和誉生物医药科技有限公司 一种kras抑制剂及其制备和在药学上的应用
WO2023114954A1 (en) 2021-12-17 2023-06-22 Genzyme Corporation Pyrazolopyrazine compounds as shp2 inhibitors
TW202340202A (zh) 2021-12-22 2023-10-16 美國加利福尼亞大學董事會 Gtp酶抑制劑及其用途
WO2023117681A1 (en) 2021-12-22 2023-06-29 Boehringer Ingelheim International Gmbh Heteroaromatic compounds for the treatment of cancer
WO2023125989A1 (zh) * 2021-12-31 2023-07-06 上海医药集团股份有限公司 一种喹唑啉类化合物及其应用
WO2023137223A1 (en) * 2022-01-17 2023-07-20 Newave Pharmaceutical Inc. Pan-kras inhibitors and uses thereof
WO2023154766A1 (en) 2022-02-09 2023-08-17 Quanta Therapeutics, Inc. Kras modulators and uses thereof
WO2023152255A1 (en) 2022-02-10 2023-08-17 Bayer Aktiengesellschaft Fused pyrimidines as kras inhibitors
EP4227307A1 (en) 2022-02-11 2023-08-16 Genzyme Corporation Pyrazolopyrazine compounds as shp2 inhibitors
WO2023172940A1 (en) 2022-03-08 2023-09-14 Revolution Medicines, Inc. Methods for treating immune refractory lung cancer
TW202346292A (zh) 2022-03-28 2023-12-01 美商尼坎醫療公司 作為週期蛋白依賴性激酶２抑制劑的磺醯胺基衍生物
WO2023194310A1 (en) 2022-04-04 2023-10-12 Sanofi Therapeutic combination of kras g12c inhibitor and tead inhibitor
WO2023199180A1 (en) 2022-04-11 2023-10-19 Novartis Ag Therapeutic uses of a krasg12c inhibitor
WO2023220421A1 (en) * 2022-05-13 2023-11-16 Ranok Therapeutics (Hangzhou) Co. Ltd. Inhibitors of kras(g12d)
CN117164580A (zh) * 2022-05-27 2023-12-05 苏州泽璟生物制药股份有限公司 一种kras g12c抑制剂的制备方法及其中间体
WO2023240024A1 (en) 2022-06-08 2023-12-14 Nikang Therapeutics, Inc. Sulfamide derivatives as cyclin-dependent kinase 2 inhibitors
WO2023240263A1 (en) 2022-06-10 2023-12-14 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2023244604A1 (en) * 2022-06-14 2023-12-21 Mirati Therapeutics, Inc. Tetrahydropyridopyrimidine pan-kras inhibitors
WO2023244615A1 (en) * 2022-06-15 2023-12-21 Mirati Therapeutics, Inc. Azaquinazoline pan-kras inhibitors
GB202212641D0 (en) 2022-08-31 2022-10-12 Jazz Pharmaceuticals Ireland Ltd Novel compounds
CN116640104B (zh) * 2023-05-24 2024-04-02 杭州科耀医药科技有限公司 一种替洛利生的工业合成方法

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA03005854A (es) 2001-01-02 2003-09-10 Hoffmann La Roche Derivados de quinazolona como antagonistas del receptor adrenergico alfa 1a/b.
US7105667B2 (en) 2001-05-01 2006-09-12 Bristol-Myers Squibb Co. Fused heterocyclic compounds and use thereof
WO2002088079A2 (en) 2001-05-01 2002-11-07 Bristol-Myers Squibb Company Dual inhibitors of pde 7 and pde 4
NZ590160A (en) 2003-11-21 2012-07-27 Array Biopharma Inc AKT protein kinase inhibitors
US20080051387A1 (en) 2006-06-09 2008-02-28 Yuelian Xu Tetrahydropyrido[3,4-d]pyrimidines and related analogues
US9259426B2 (en) * 2006-07-20 2016-02-16 Gilead Sciences, Inc. 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections
EP2099770B1 (en) 2006-12-21 2015-06-10 Sloan-Kettering Institute for Cancer Research Pyridazinones and furan-containing compounds
WO2008103470A2 (en) 2007-02-21 2008-08-28 Trustees Of Columbia University In The City Of New York Oncogenic-ras-signal dependent lethal compounds
WO2009047255A1 (en) 2007-10-09 2009-04-16 Ucb Pharma, S.A. Heterobicyclic compounds as histamine h4-receptor antagonists
CA2719376A1 (en) 2008-04-07 2009-10-15 Gilead Sciences, Inc. 2h-benzo[b][1,4]oxazin-3(4h)-one derivatives for use as stearoyl coa desaturase inhibitors
JP2011529920A (ja) 2008-07-31 2011-12-15 ジェネンテック， インコーポレイテッド ピリミジン化合物、組成物及び使用方法
WO2010120996A1 (en) * 2009-04-17 2010-10-21 Wyeth Llc 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses
EP2518064A1 (en) 2009-12-25 2012-10-31 Mochida Pharmaceutical Co., Ltd. Novel aryl urea derivative
MX2012007684A (es) 2009-12-30 2012-10-05 Avila Therapeutics Inc Modificacion covalente ligando dirigida de proteina.
EP2681215B1 (en) 2011-02-28 2015-04-22 Array Biopharma, Inc. Serine/threonine kinase inhibitors
WO2012171015A2 (en) * 2011-06-10 2012-12-13 Translational Genomics Research Institute Therapeutic combination for cancer treatment
US20150087628A1 (en) 2012-04-10 2015-03-26 The Regents Of The University Of California Compositions and methods for treating cancer
WO2014011973A2 (en) 2012-07-13 2014-01-16 The Trustees Of Columbia University In The City Of New York Quinazolinone-based oncogenic-ras-selective lethal compounds and their use
US9227978B2 (en) 2013-03-15 2016-01-05 Araxes Pharma Llc Covalent inhibitors of Kras G12C
US9745319B2 (en) 2013-03-15 2017-08-29 Araxes Pharma Llc Irreversible covalent inhibitors of the GTPase K-Ras G12C
EP3401314B1 (en) 2013-03-15 2023-11-08 Araxes Pharma LLC Covalent inhibitors of kras g12c
TWI659021B (zh) 2013-10-10 2019-05-11 亞瑞克西斯製藥公司 Ｋｒａｓ ｇ１２ｃ之抑制劑
WO2015054572A1 (en) 2013-10-10 2015-04-16 Araxes Pharma Llc Inhibitors of kras g12c
JP6279963B2 (ja) 2014-04-15 2018-02-14 株式会社神戸製鋼所 チタンまたはチタン合金からなるスラブの連続鋳造装置
MA40074A (fr) 2014-05-30 2015-12-03 Univ Columbia Composés liant ras multivalents
WO2016025650A1 (en) * 2014-08-13 2016-02-18 Celgene Avilomics Research, Inc. Combinations of an erk inhibitor and a cdk4/6 inhibitor and related methods
JO3556B1 (ar) 2014-09-18 2020-07-05 Araxes Pharma Llc علاجات مدمجة لمعالجة السرطان
WO2016049568A1 (en) 2014-09-25 2016-03-31 Araxes Pharma Llc Methods and compositions for inhibition of ras
WO2016049565A1 (en) 2014-09-25 2016-03-31 Araxes Pharma Llc Compositions and methods for inhibition of ras
AR102094A1 (es) 2014-09-25 2017-02-01 Araxes Pharma Llc Inhibidores de proteínas kras con una mutación g12c
US10017540B2 (en) 2015-03-11 2018-07-10 California Institute Of Technology Cyclic peptide binder against oncogenic K-Ras
ES2898765T3 (es) 2015-04-10 2022-03-08 Araxes Pharma Llc Compuestos de quinazolina sustituidos y métodos de uso de los mismos
EP3283462B1 (en) 2015-04-15 2020-12-02 Araxes Pharma LLC Fused-tricyclic inhibitors of kras and methods of use thereof
WO2016172692A1 (en) 2015-04-24 2016-10-27 H. Lee Moffitt Cancer Center And Research Institute, Inc. Mutant kras inhibitors
EA201792443A1 (ru) 2015-05-06 2018-10-31 Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния МОДУЛЯТОРЫ K-Ras
US10144724B2 (en) 2015-07-22 2018-12-04 Araxes Pharma Llc Substituted quinazoline compounds and methods of use thereof
RU2018113709A (ru) 2015-09-24 2019-10-30 Айонис Фармасьютикалз, Инк. Модуляторы экспрессии kras
US10875842B2 (en) 2015-09-28 2020-12-29 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
WO2017058805A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
US10882847B2 (en) 2015-09-28 2021-01-05 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
WO2017058915A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
US10858343B2 (en) 2015-09-28 2020-12-08 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
WO2017058768A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
WO2017058902A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
JP2018533939A (ja) 2015-10-19 2018-11-22 アラクセス ファーマ エルエルシー Ｒａｓの阻害剤をスクリーニングするための方法
EP3365686A4 (en) 2015-10-22 2019-03-27 The Scripps Research Institute CYSTEINE-RESPONSIVE PROBES AND USES THEREOF
WO2017080980A1 (en) 2015-11-09 2017-05-18 Astrazeneca Ab Dihydropyrrolopyrazinone derivatives useful in the treatment of cancer
WO2017079864A1 (en) 2015-11-12 2017-05-18 Hangzhou Yier Biotech Co., Ltd. Treatment of cancers related to chronically active ras
EA038635B9 (ru) 2015-11-16 2021-10-26 Араксис Фарма Ллк 2-замещенные соединения хиназолина, содержащие замещенную гетероциклическую группу, и способы их применения
US9988357B2 (en) 2015-12-09 2018-06-05 Araxes Pharma Llc Methods for preparation of quinazoline derivatives
AU2017266911B2 (en) * 2016-05-18 2021-09-02 Array Biopharma, Inc. KRas G12C inhibitors
US10646488B2 (en) 2016-07-13 2020-05-12 Araxes Pharma Llc Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
CN110036010A (zh) 2016-09-29 2019-07-19 亚瑞克西斯制药公司 Kras g12c突变蛋白的抑制剂
EP3523289A1 (en) 2016-10-07 2019-08-14 Araxes Pharma LLC Heterocyclic compounds as inhibitors of ras and methods of use thereof
WO2018069871A2 (en) 2016-10-13 2018-04-19 Sorrento Therapeutics, Inc. Anti-kras binding proteins
MX2019006299A (es) 2016-11-30 2019-11-12 Bantam Pharmaceutical Llc Compuestos de pirazola sustituida y metodos para usarlos para el tratamiento de enfermedades hiperproliferativas.
EP3548024A2 (en) 2016-11-30 2019-10-09 Bantam Pharmaceutical, LLC Methods of using substituted pyrazole and pyrazole compounds and for treatment of hyperproliferative diseases
BR112019012263A2 (pt) 2016-12-15 2020-01-28 Univ California composições e métodos para tratar câncer
BR112019012976A2 (pt) 2016-12-22 2019-12-31 Amgen Inc inibidores de kras g12c e métodos de uso dos mesmos
CN110167928A (zh) 2016-12-22 2019-08-23 勃林格殷格翰国际有限公司 作为sos1抑制剂的新型经苄基氨基取代的喹唑啉和衍生物
US10344026B2 (en) 2017-01-18 2019-07-09 Nantbio, Inc. Compositions and methods of targeting mutant K-ras
EP3573970A1 (en) 2017-01-26 2019-12-04 Araxes Pharma LLC 1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer
US11358959B2 (en) 2017-01-26 2022-06-14 Araxes Pharma Llc Benzothiophene and benzothiazole compounds and methods of use thereof
EP3573954A1 (en) 2017-01-26 2019-12-04 Araxes Pharma LLC Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
WO2018140600A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc Fused hetero-hetero bicyclic compounds and methods of use thereof
EP3573971A1 (en) 2017-01-26 2019-12-04 Araxes Pharma LLC 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer
EP3573966A1 (en) 2017-01-26 2019-12-04 Araxes Pharma LLC Fused n-heterocyclic compounds and methods of use thereof
JOP20190186A1 (ar) 2017-02-02 2019-08-01 Astellas Pharma Inc مركب كينازولين
EP3612526A2 (en) 2017-04-20 2020-02-26 The Regents of the University of California K-ras modulators
IL293443A (en) 2017-09-08 2022-07-01 Amgen Inc kras g12c inhibitors and methods of using them
HUE061599T2 (hu) * 2017-11-15 2023-07-28 Mirati Therapeutics Inc KRas G12C inhibotorok
US10597405B2 (en) 2017-12-08 2020-03-24 Astrazeneca Ab Chemical compounds
TW201942115A (zh) 2018-02-01 2019-11-01 美商輝瑞股份有限公司 作為抗癌藥之經取代的喹唑啉和吡啶並嘧啶衍生物
TW201942116A (zh) 2018-02-09 2019-11-01 美商輝瑞股份有限公司 作為抗癌劑之四氫喹唑啉衍生物

Also Published As

Publication number Publication date
US20210269432A1 (en) 2021-09-02
ES2863873T3 (es) 2021-10-11
EP3458445A4 (en) 2019-11-13
AU2017266911B2 (en) 2021-09-02
US20190062330A1 (en) 2019-02-28
WO2017201161A1 (en) 2017-11-23
KR102444509B1 (ko) 2022-09-19
JP2019516718A (ja) 2019-06-20
SG11201810171SA (en) 2018-12-28
US10125134B2 (en) 2018-11-13
IL262867A (en) 2019-03-31
KR20190039475A (ko) 2019-04-12
US10633381B2 (en) 2020-04-28
IL262867B (en) 2022-01-01
JP7039489B2 (ja) 2022-03-22
EP3458445A1 (en) 2019-03-27
AU2017266911A1 (en) 2018-12-06
CN109843856B (zh) 2023-05-02
US11267812B2 (en) 2022-03-08
US20180072723A1 (en) 2018-03-15
EP3458445B1 (en) 2021-02-17
CA3024523A1 (en) 2017-11-23
CN109843856A (zh) 2019-06-04

Similar Documents

Publication Publication Date Title
PH12020550622A1 (en) Kras g12c inhibitors
MX2018013983A (es) Inhibidores g12c de kras.
MX2022002465A (es) Inhibidores de kras g12d.
MX2018008052A (es) Inhibidores de desmetilasa especifica de lisina 1 (lsd1).
PH12017500509A1 (en) Benzyl substituted indazoles as bub1 inhibitors
MX2019001125A (es) Inhibidores de cinasa macrociclica.
PH12016500330B1 (en) Certain chemical entities, compositions, and methods
MY187540A (en) Compounds active towards bromodomains
MX2015008999A (es) Inhibidores mk2 y usos de los mismos.
PH12015502041B1 (en) Heteroaryl compounds and uses thereof
MX2016003843A (es) Inhibidores de cinasas asociadas al receptor de interleucina 1 (irak) y usos de los mismos.
MX369691B (es) Inhibidores de glutaminasa y métodos de empleo.
MY192588A (en) Pharmaceutical compounds
SG10201808940WA (en) Nox inhibitor and nfкb inhibitor containing methoxyflavone
MX2016015565A (es) Ciertos inhibidores de la proteina quinasa.
SG10201902326XA (en) Mk2 inhibitors and uses thereof
PH12018500446A1 (en) Pyridinone dicarboxamide for use as bromodomain inhibitors
MX2020001756A (es) Compuestos deuterados del inhibidor vmat y el uso de dichos compuestos.
MX2017004808A (es) Combinaciones que comprenden siponimod y laquinimod para el tratamiento de la esclerosis multiple.
SA519410093B1 (ar) مركبات بيريميدو بيريميدينون مفيدة كمثبطات دبليو إى إى-1 كيناز
MX2017013875A (es) Ciertos inhibidores de la proteína quinasa.
MX2016001446A (es) Inhibidores de heterobicicloaril rorc2 y metodos de uso de los mismos.
MX2018006700A (es) Inhibidores aza-bencimidazol de peptidilarginina desiminasa (pad4).
PH12017500348B1 (en) Tetrahydroquinoline derivatives as bromodomain inhibitors
EA201890364A1 (ru) СОЕДИНЕНИЯ, ПРИГОДНЫЕ ДЛЯ ИНГИБИРОВАНИЯ ROR-ГАММА-t